Erich Harnack (1852-1915) and a short history of apomorphine

Abstract

Apomorphine, now established as an efficacious therapy for refractory motor fluctuations in levodopa-treated Parkinson's disease, has a long and chequered history in medical and veterinary therapeutics. The preclinical in vivo pharmacological effects of apomorphine were first studied about 150 years ago following which the drug was introduced for the treatment of behavioural vices in domesticated animals. Erich Harnack's early pharmacological studies in Dorpat (now Tartu, Estonia), where he belonged to the pharmacological dynasty of Buchheim and Schmiedeberg, are of particular historical significance as he emphasised that while apomorphine had potent emetic effects, the drug also had complex effects on the central nervous system. © 2013 S. Karger AG, Basel.